MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy

Part of the Methods in Molecular Biology book series (MIMB, volume 1317)

Abstract

Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC.

Key words

Cell-based tumor vaccine MIDGE vector Non-viral vectors Electroporation Transient transfection 

References

  1. 1.
    Schakowski F et al (2001) A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3:793–800PubMedCrossRefGoogle Scholar
  2. 2.
    Moreno S et al (2004) DNA immunisation with minimalistic expression constructs. Vaccine 22:1709–1716PubMedCrossRefGoogle Scholar
  3. 3.
    Schmidt M, Volz B, Wittig B (2005) MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies. In: Knäblein J, Müller RH (eds) Modern Biopharmaceutical. WILEY-VCH Verlag, Weinheim, pp 1–29Google Scholar
  4. 4.
    Schakowski F et al (2007) Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 21:17–23PubMedGoogle Scholar
  5. 5.
    Endmann A et al (2010) Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 28:3642–369PubMedCrossRefGoogle Scholar
  6. 6.
    Kobelt D (2014) Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector. Mol Oncol 8:609–619PubMedCrossRefGoogle Scholar
  7. 7.
    Keenan BP, Jaffee EM (2012) Whole cell vaccines–past progress and future strategies. Semin Oncol 39:276–286PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Schendel DJ et al (2000) Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7:2007–2014PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson BD et al (2005) Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother 28:449–460PubMedCrossRefGoogle Scholar
  10. 10.
    Dzojic H et al (2006) Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66:831–838PubMedCrossRefGoogle Scholar
  11. 11.
    Loskog A, Totterman TH (2007) CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7:23–28PubMedCrossRefGoogle Scholar
  12. 12.
    Ruybal P et al (2008) Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. Vaccine 26:697–705PubMedCrossRefGoogle Scholar
  13. 13.
    Zhan Y et al (2011) GM-CSF increases cross-presentation and CD103 expression by mouse CD8(+) spleen dendritic cells. Eur J Immunol 41:2585–2595PubMedCrossRefGoogle Scholar
  14. 14.
    Morre M, Beq S (2012) Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 7:55–68PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Schmidt M et al (2006) Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 61:56–63PubMedCrossRefGoogle Scholar
  16. 16.
    Kapp K et al (2014) Genuine immunomodulation with dslim. Mol Ther Nucleic Acids 3:e170PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Schmidt M et al (2015) Design and structural requirements of the potent and safe TLR-9agonistic immunomodulator MGN1703. Nucleic Acid Ther (in press)Google Scholar
  18. 18.
    Schmoll HJ et al (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol, Epub ahead of printGoogle Scholar
  19. 19.
    Wittig B et al (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Crit Rev Oncol Hematol 94:31–44Google Scholar
  20. 20.
    Grünwald V et al (2014) Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study. J Clin Oncol 32(15 suppl), e15590Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Mologen AG BerlinBerlinGermany
  2. 2.Mologen AGBerlinGermany
  3. 3.Foundation Institute Molecular Biology and BioinformaticsFreie Universität BerlinBerlinGermany

Personalised recommendations